Gender differences in the natural history of HIV infection. NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Gender differences in the natural history of HIV infection.

Int Conf AIDS. 1992 Jul 19-24;8(1):Mo10 (abstract no. MoC 0030). Unique Identifier : AIDSLINE ICA8/92399986
Szabo S; Miller LH; Sacks HS; Gurtman AC; Rose DN; Kee RA; Cheung TW; Cohen SE; Mount Sinai School of Medicine, New York, NY.


Abstract: OBJECTIVE: To compare the natural history of HIV infection in men and women. METHODS: Retrospective chart review of 149 HIV infected women (HW) and 111 HIV infected men (HM) registered in the Infectious Disease clinic from 8/87 to 7/91 at an inner city tertiary care center. RESULTS: 149 HW age 33 +/- 7.6 yrs (mean +/- SD) and 111 HM, age 36 +/- 8.5 yrs were followed for 11.2 +/- 11.0 and 12.3 +/- 11.1 mos, respectively. 52% of HW and 57% of HM were hispanic, 39% of HW and 30% of HM were black and 9% of HW and 13% of HM were white. 48% of HW acquired HIV heterosexually and 37% via IVDU; 29% of HM were homosexual, 10% were heterosexual and 48% were IVDU. At initial presentation to clinic, 54% of HW and 37% of HM were asymptomatic (asx), 30% of HW and 43% of HM had ARC and 16% of HW and 20% of HM had AIDS (p less than .05); HW had CD4 count of 336 +/- 294; HM had CD4 count of 247 +/- 269 (p less than .05). The frequencies of AIDS defining OI's in HW and HM were: PCP (46% and 33%), candida esophagitis (17% and 8%), disseminated (D) MAI (0 and 17%), toxoplasmosis (13% and 0%), extrapulmonary tuberculosis (13% and 8%), CMV retinitis (4% and 0%), wasting syndrome (4% and 8%), cryptococcal meningitis (4% and 4%), KS (0% and 8%), D histoplasmosis, dementia and D herpes (0% and 4%) (all p greater than .05). Overall progression to AIDS was 8% for HW and 17% for HM, progression to AIDS for asx HW was 2.5% and for asx HM was 7.3%; for HW with ARC 18% and HM with ARC 25%. Overall survival for HW was 84.6% and for HM 89.2%; for asx HW 95% and asx HM 100%, for HW with ARC 77.8% and HM with ARC 91.7%, and HW with AIDS 62.5% and HM with AIDS 64% (all p greater than .05). CONCLUSIONS: At our center, HW entered care at earlier stages of disease, with higher CD4 counts, than HM. Patterns of OIs, survival and disease progression were similar in HW and HM. Thus, as the epidemic evolves, early concerns that HIV infection is more severe or different in women are not being substantiated. Prospective studies are needed.
Keywords: Acquired Immunodeficiency Syndrome/EPIDEMIOLOGY Adult AIDS-Related Complex/EPIDEMIOLOGY Comorbidity Comparative Study CD4-Positive T-Lymphocytes Disease Susceptibility Ethnic Groups Female Human HIV Infections/COMPLICATIONS/*EPIDEMIOLOGY/TRANSMISSION Leukocyte Count Male New York City/EPIDEMIOLOGY Opportunistic Infections/COMPLICATIONS/*EPIDEMIOLOGY Retrospective Studies Sex Behavior Sex Factors Substance Abuse, Intravenous/COMPLICATIONS/EPIDEMIOLOGY Survival Rate ABSTRACTKWDacquiredimmunodeficiencysyndrome/epidemiologyadultaids-relatedcomplex/epidemiologycomorbiditycomparativestudycd4-positivet-lymphocytesdiseasesusceptibilityethnicgroupsfemalehumanhivinfections/complications/KWDepidemiology/transmissionleukocytecountmalenewyorkcity/epidemiologyopportunisticinfections/complications/KWDepidemiologyretrospectivestudiessexbehaviorsexfactorssubstanceabuse,intravenous/complications/epidemiologysurvivalrateabstract
921230
M92C5361

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .